Clinical trial
Diagnostic Performance of Salivary Interleukin-8 and Serum Interleukin-6 for Oral Potentially Malignant Disorders: Effect Modification by Smoking Status - A Cross-Sectional Study
NCT07915570 is registered in ClinicalTrials.gov with British University In Egypt as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Diagnostic Performance of Salivary Interleukin-8 and Serum Interleukin-6 for Oral Potentially Malignant Disorders: Effect Modification by Smoking Status - A Cross-Sectional Study
- Lead sponsor
- British University In Egypt
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- October 1, 2026
- Completion date
- January 30, 2027
- Enrollment
- 250 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
oral leukoplakia, oral lichen planus, oral potentially malignant disorders, oral squamous cell carcinoma, smoking
Arms
As registered; 5 arms.
-
Healthy Controls - Never-Smokers
Adults with clinically healthy oral mucosa and no current or previous oral potentially malignant disorder or oral cancer, who have never smoked (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, periodontal and tobacco-use assessment.
-
Healthy Controls - Current Smokers
Adults with clinically healthy oral mucosa and no current or previous oral potentially malignant disorder or oral cancer, who are current smokers (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, periodontal and tobacco-use assessment.
-
OPMD - Never-Smokers
Adults who have never smoked, with a histopathologically confirmed oral potentially malignant disorder (oral lichen planus or oral leukoplakia) and no definitive treatment of the lesion before sample collection (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, histopathological, periodontal and tobacco-use assessment.
-
OPMD - Current Smokers
Adults who are current smokers, with a histopathologically confirmed oral potentially malignant disorder (oral lichen planus or oral leukoplakia) and no definitive treatment of the lesion before sample collection (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, histopathological, periodontal and tobacco-use assessment.
-
OSCC - Current Smokers (Exploratory)
Adults who are current smokers, with histopathologically confirmed oral squamous cell carcinoma (n = 50). Exploratory cohort compared with current-smoking OPMD patients; not included in the primary healthy control versus OPMD comparisons. Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, histopathological (tumor grade), periodontal and tobacco-use assessment.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Salivary IL-8 Concentration
Salivary interleukin-8 (IL-8) concentration, measured using an enzyme-linked immunosorbent assay (ELISA) and expressed in pg/mL. Concentrations are compared between healthy controls and participants with oral potentially malignant disorders (OPMDs), with analyses stratified by smoking status where applicable.
-
Serum IL-6 Concentration
Serum interleukin-6 (IL-6) concentration, measured using an ELISA and expressed in pg/mL. Concentrations are compared between healthy controls and participants with OPMDs, with analyses stratified by smoking status where applicable.
Lead sponsor's other trials
British University In Egypt, most recent start first.
+64 more trials See the organization page
Similar trials
Same condition (Leukoplakia, Oral) and phase, most recent start first.
+14 more trials See the condition page